Table 2.
Population modeling | Bootstrap (n=1000) | ||||
---|---|---|---|---|---|
Parameter - Symbol | Estimates | RSE (%) | Median | 95% CI | Biasa (%) |
CL/F (L.hr−1) − | 19.7 | 6.30 | 19.6 | 17.5 – 22.1 | −0.10 |
CYP3A5*3*6*7 on CL/F | |||||
CIMCYP3A5 − | 1.45 | 9.90 | 1.46 | 1.20 – 1.78 | 0.01 |
CEMCYP3A5 − | 2.25 | 13.6 | 2.28 | 1.64 – 3.01 | 0.03 |
V/F (L) − | 234 | 10.2 | 231 | 190 – 276 | −3.00 |
CLp/F (L.hr−1) − | 52.6 | 9.50 | 53.2 | 44.1 – 63.6 | 0.60 |
Vp/F (L) − | 403 | 20.1 | 404 | 275 – 572 | 1.00 |
ka (hr−1) − | 4.21 | 20.3 | 4.14 | 2.77 – 5.74 | −0.07 |
Lag time (hr) − | 0.828 | 3.80 | 0.830 | 0.740 – 0.873 | 0.002 |
Between-subject variability | |||||
BSV CL/F (CV%) − | 37.0 | 6.20 | 36.1 | 30.9 – 40.7 | −0.9 |
BSV V/F (CV%) − | 76.7 | 12.1 | 76.0 | 56.0 – 93.5 | −0.7 |
BSV CLp/F (CV%) − | 48.6 | 16.5 | 47.8 | 29.4 – 64.9 | −0.8 |
BSV ka (CV%) − | 69.4 | 16.5 | 68.6 | 48.3 – 93.9 | −0.8 |
Residual variability | |||||
Proportional error − | 9.00 | 5.60 | 8.90 | 8.04 – 9.83 | −0.1 |
RSE (%) Percent relative standard error of the estimate; 95% CI 95th Confidence interval: 2.5 and 97.5th percentiles, BSV Between-subject variability expressed as percent coefficient of variation (CV%); CL/F =Apparent elimination clearance; CLp/F Apparent distribution clearance; V/F Apparent central volume of distribution; Vp/F Apparent peripheral volume of distribution; ka Absorption rate.
The bias of each parameter was calculated by computing the difference between the median value derived from the bootstrap and the final parameter estimate.
99% of the bootstraps runs minimized successfully (990/1000).
Final pharmacokinetic model (typical individual values):
and
where H1 = 1 for CYP3A5 intermediate metabolizers (cIMCYP3A5) and H2 = 1 for CYP3A5 extensive metabolizers (cEMCYP3A5). TBW Total body weight (kg)